학술논문
Baricitinib Treatment of Coronavirus Disease 2019 Is Associated With a Reduction in Secondary Infections
BRIEF REPORT
BRIEF REPORT
Document Type
Report
Author
Sweeney, Daniel A.; Tuyishimire, Bonifride; Ahuja, Neera; Beigel, John H.; Beresnev, Tatiana; Cantos, Valeria D.; Castro, Jose G.; Cohen, Stuart H.; Cross, Kaitlyn; Dodd, Lori E.; Erdmann, Nathan; Fung, Monica; Ghazaryan, Varduhi; George, Sarah L.; Grimes, Kevin A.; Hynes, Noreen A.; Julian, Kathleen G.; Kandiah, Sheetal; Kim, Hannah Jang; Levine, Corri B.; Lindholm, David A.; Lye, David C.; Maves, Ryan C.; Oh, Myoung- don; Paules, Catharine; Rapaka, Rekha R.; Short, Willam R.; Tomashek, Kay M.; Wolfe, Cameron R.; Kalil, Andre C.
Source
Open Forum Infectious Diseases. May 2023, Vol. 10 Issue 5
Subject
Language
English
ISSN
2328-8957
Abstract
The second stage of the National Institutes of Health-sponsored Adaptive COVID-19 Treatment Trial (ACTT-2) compared the combination of baricitinib plus remdesivir with that of placebo plus remdesivir in adult patients [...]
We performed a secondary analysis of the National Institutes of Health-sponsored Adaptive COVID-19 Treatment Trial (ACTT-2) randomized controlled trial and found that baricitinib was associated with a 50% reduction in secondary infections after controlling for baseline and postrandomization patient characteristics. This finding provides a novel mechanism of benefit for baricitinib and supports the safety profile of this immunomodulator for the treatment of coronavirus disease 2019. Keywords. baricitinib; COVID-19; secondary infections.
We performed a secondary analysis of the National Institutes of Health-sponsored Adaptive COVID-19 Treatment Trial (ACTT-2) randomized controlled trial and found that baricitinib was associated with a 50% reduction in secondary infections after controlling for baseline and postrandomization patient characteristics. This finding provides a novel mechanism of benefit for baricitinib and supports the safety profile of this immunomodulator for the treatment of coronavirus disease 2019. Keywords. baricitinib; COVID-19; secondary infections.